Literature DB >> 7836337

Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?

W A Brown1, W Harrison.   

Abstract

BACKGROUND: The question was asked whether patients who discontinue one serotonin selective reuptake inhibitor (SSRI) because of side effects can be treated successfully with another SSRI.
METHOD: 113 patients with major depression who had discontinued fluoxetine because of side effects were enrolled in an open, multicenter, 8-week study designed to evaluate the tolerability and efficacy of sertraline. After a washout period of at least 3 weeks following fluoxetine discontinuation and an additional 1-week, single-blind, placebo washout period, patients began treatment with 50 mg of sertraline once daily. Doses were titrated upward as necessary to a maximum daily dose of 200 mg. Depressive symptoms and adverse events were evaluated weekly.
RESULTS: Based on the Clinical Global Impressions Scale, 79 (71.8%) of 110 patients evaluated for efficacy were "much" or "very much" improved relative to baseline. Only 11 (9.8%) of 112 patients discontinued sertraline because of adverse reactions.
CONCLUSION: These results suggest that patients who discontinue one SSRI because of side effects can be treated successfully with another.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836337

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Chronic Functional Abdominal Pain (CFAP).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

Review 3.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 4.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 5.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 6.  Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.

Authors:  P L Hensley; H G Nurnberg
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

8.  Possible cross-sensitivity between sertraline and paroxetine in a panic disorder patient.

Authors:  Praveen H Khairkar; Govind M Bang; Adarshlata B Singh; Prashant G Tiple
Journal:  Indian J Pharmacol       Date:  2010-04       Impact factor: 1.200

Review 9.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

10.  From the Bench to the Trench: A Comparison of Sertraline Treatment of Major Depression in Clinical and Research Patient Samples.

Authors:  R Bruce Lydiard; Philip Perera; Evan Batzar; Cathryn M. Clary
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.